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ASSESSMENT OF THE EFFECT OF A PROTEIN CALORIE SUPPLEMENT ON 
 
CHANGE IN CD4 COUNT AMONG ART-NAÏVE FEMALE TB PATIENTS 
 
CO-INFECTED WITH HIV IN DAR ES SALAAM, TANZANIA 
 
ALBERT KATANA MAGOHE 
ABSTRACT 
Rationale:  Tuberculosis and HIV infection together form a highly mortal combination. 
Even after the advent of highly active antiretroviral therapy (HAART) medications, 
management for Tuberculosis and HIV/AIDS still remains a challenge. Poor outcomes 
(in both morbidity and mortality) are still being witnessed throughout the world, and 
especially in the poorly developed countries that bear the bulk of the burden of the cases.  
It is assumed that one of the major contributors to the poor outcomes is poor nutritional 
status resulting from the disease process itself, poverty and toxicity from medications 
being used to treat these diseases that substantially reduce appetite. An assessment of the 
role that nutritional status has on change in CD4 as a surrogate marker of disease 
progression is therefore of importance. 
 
Objectives: To evaluate the role that nutritional supplementation has on change in CD4 
in TB patients co-infected with HIV who are receiving standard care of treatment. 
 
Methods: Data from a randomized controlled trial of a Protein Calorie Supplement 
(PCS) were used. To assess the effect of randomization to a nutritional supplement, 
baseline characteristics were compared among the intervention and the control groups 
		 
 v 
and confounder variables, such as age, BMI, baseline CD4, socioeconomic status, 
previous exposure to TB and compliance with HAART medication were analyzed and 
adjusted for in a model using multivariate linear regression.  
 
Results: 151 HIV-infected women with TB disease were enrolled; 72 received PCS 
while 79 did not. We found that the PCS intervention had no significant effect on change 
in CD4 between baseline and 8 months. Average change in CD4 count was similar for 
intervention and control groups (204 vs. 207 units). This similarity persisted after 
adjusting for baseline BMI and previous TB disease. 
 
Conclusion: Randomization (i.e. nutritional supplement) did not have a significant effect 
on change in CD4 count among study participants. However, an effect could have been 
masked by high compliance with ART. 
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I: Summary: 
 
Despite efforts to control Tuberculosis, it still ranks high among diseases of public health 
interest, especially since the advent of the HIV/AIDS epidemic. Together, these two 
diseases have formed a highly mortal combination.(1–3) After the advent of highly active 
antiretroviral therapy (HAART) medications, treatment for Tuberculosis and HIV/AIDS 
has been improving. (4, 5) However poor outcomes (in both morbidity and mortality) are 
being witnessed throughout the world, and especially in the poorly developed countries 
that bear the bulk of the burden of the cases.(6–9) 
 
It is assumed that one of the major contributors to the poor outcomes is poor nutritional 
status resulting from the disease process itself, poverty and toxicity from medications 
being used to treat these diseases that substantially reduce appetite. Other factors known 
to be associated with poor HIV/TB outcomes include CD4 count, age, body mass index, 
socioeconomic status and level of education. (10–14)  
 
We therefore performed a randomized controlled study to assess the impact of 
supplementing HIV/TB patients with a protein calorie supplement to meet the daily-
required allowances for protein and energy. The results from this study are expected to 
offer insight into the effect that nutritional supplements can have on the immune function 
of TB/HIV patients with CD4 above 200 at the time of enrollment. The study was done in 
Dar Es Salaam, Tanzania between 2011 and 2014. A total of 151 HIV/TB co-infected 
women were enrolled, randomized and followed up for a year for the outcome of interest, 
change in CD 4 levels. All participants were recruited from national tuberculosis and 
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leprosy programme (NTLP) sites in Dar es Salaam. 
 
An assessment of a CD4 change within 6 months of completion of anti TB medication 
and a year after initiation of ART will offer us an insight on the role that nutritional 
supplementation can play among those receiving standard therapy for TB and HIV.  
 
II. Background: 
The global burden of TB is substantial, with about a third of the global population 
infected with M. tuberculosis. According to WHO it is estimated in 2013 there were 9 
million new cases of TB disease (15), (1.1 million of which were among people infected 
with HIV) and 1.3 million TB associated deaths. 2014 estimates show that about 35 
million individuals are infected with HIV, 1.5 million of whom died of AIDS related 
illnesses.(16) 40% of deaths among people living with HIV are thought to be precipitated 
by the co-prevalence of TB disease.   Even with appropriate treatment, TB patients co-
infected with HIV have a more drastic progression of their HIV illness than those without 
TB.(17, 18) 
 
Adequate nutritional status is key to successful management of TB and HIV cases, and 
even more importantly among HIV-infected TB patients. (10, 11, 19) However studies 
have shown that most of these patients also have poor nutritional status, some of which 
can be explained by poor dietary practices.(20) 
 
Findings from most studies on the role of macronutrient supplementation among patients 
receiving TB/HIV treatment have been inconclusive. Marginal benefits have been 
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observed among those co-infected patients with severe malnutrition.(21–23) A pilot study 
in India showed no significant difference in TB outcomes at the end of macronutrient 
supplementation. However, the small number of participants in the study could have 
affected these findings. (21) 
 
Beneficial outcomes have been observed on studies exploring the role of micronutrient 
supplementation. Adequate iron and Vitamin D status (achieved through 
supplementation) has been shown to lessen the risk of TB relapse especially with 
improved nutritional pointers such as BMI in patients with TB, with or without HIV 
infection.(24, 25)  
 
A study on energy–protein supplementation to patients who had pulmonary TB and HIV 
did not show any overall effects on weight and body composition. However there was a 
marginally significant improvement in strength of handgrip used as a proxy to measure 
body strength.(26)  
 
Among others, factors contributing to the poor nutritional status include inadequate 
intake, inadequate uptake of ingested food, body exhaustion due to the dual disease 
process and toxicities of the medications used to treat these infections.(27) 
 
Studies to quantify the magnitude of deficits in both calories and energy have indicated 
substantial deficits in both protein and energy among populations of people infected with 
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TB and HIV. Inadequate intake, uptake and excess losses have been noted as some of the 
reasons of the observed deficits.  One such study among adult participants in Tanzania 
enumerated a deficit of 1000 Kcal and 40 g of protein on daily nutritional requirements 
for such patients. (28) Such significant deficits are thought to contribute towards poor 
outcomes among patients co infected with HIV and TB resulting in the high rates of 
morbidity and mortality. 
 
In the current study, attempts to supplements such patients using a protein calorie 
supplements have therefore been undertaken. The main aim being an overall 
improvement in clinical outcomes to patients co-infected with HIV and TB. 
 
Assessment of HIV/AIDS-TB disease progression is therefore vital in evaluating the 
effect of the supplement among patients co infected with HIV and TB. Among surrogate 
markers serving this purpose is the assessment of CD4 count and subsequent CD4 change 
among HIV patients.(29) 
 
Cluster of Differentiation 4 (CD4) is a glycoprotein found on the surface of immune cells 
such as T helper cells, monocytes, macrophages, and dendritic cells. CD4+ T helper cells 
are white blood cells that are an essential part of the human immune system.(30) They 
constitute a system that specifically respond to HIV infection, and CD4 count signifies 
how strong ones body immune is against HIV.(31)  
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The measurement of CD4+ T-cell (CD4) counts is a strong predictor of progression to 
Human Immunodeficiency Syndrome (AIDS), and is also used as means of monitoring 
response to antiretroviral therapy (ART). Low CD4 counts have been shown to be 
associated with a greater risk of patients living with HIV succumbing to opportunistic 
infections, which may then progress to advanced diseases and death (2, 32). Possible 
increases or decreases in CD4 counts are directly related to HIV replication. The use of 
combinations of ART generally results in the suppression of virus replication and hence 
increased levels of CD4.(33–35) 
 
Besides HAART, several other factors are known to influence CD4 counts; these include 
host nutritional status, baseline CD4 before initiation of ART, presence of other 
comorbidities, age, body mass index, socioeconomic status and level of education.  
 
Studies have shown that, even after adjusting for potential confounders, HAART is 
known to result in an improvement in immunologic status, one feature of which is an 
upsurge in the CD4 cell count. (1–3). Studies have shown a rapid increase in CD4 cell 
count during the first few weeks followed by a prolonged period of less-rapid 
increase.(36, 37)  
 
Studies on the role that baseline CD4 has on the rate of change in CD4 count among 
patients receiving HAART have been inconclusive. Some of the studies have informed 
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that the baseline CD4 cell count impacts the rate of immune rebuilding (38, 39), whereas 
others have found no evidence of such a relation.(40–42) 
 
Age at initiation of ART has also been shown to be associated with immunologic 
response. Starting ART at a younger age has been shown to be associated with an 
improved immunologic response. (12, 13) 
 
Comorbidities and other HIV related opportunistic infections such as Kaposi sarcoma, 
Pneumocystis carinii pneumonia, oral and esophageal candidiasis, cryptococcal 
meningitis among many others have been associated with poor outcomes in HIV infected 
patients. Individuals with such commodities have been found to have poor progress 
associated with plummeting CD4 counts. (43–46) 
 
Other studies have shown that body mass index (BMI) has an effect on CD4 cell 
recovery. Very low BMI patients had a slower rate of recovery as compared to those with 
high BMI. This effect was demonstrated on patients who were on anti-retroviral therapy. 
(47–50)  
 
III. Parent study design 
A randomized controlled trial was done in which enrolled women were aged 18 years and 
above. All participants were HIV-infected with concurrent newly diagnosed TB disease. 
The study was based at a facility associated with the Muhimbili University of Health and 
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Allied Sciences. Overall the study took 3 years with individual participants followed up 
for 1 year each. The study was conducted between 2011 and 2014. 
 
a. Randomization and intervention.  
A master randomization list was generated by the Data Center at Dartmouth. A one to 
one, micronutrient supplementation (MNS) alone vs. MNS plus protein calorie 
supplementation (PCS) list was generated for each group. All subjects were started on 
their assigned intervention at the time of their first visit. During each monthly visit, 
subjects received a month supply of the intervention as per their assigned arm. 
 
A study number was given to eligible subjects from the randomization list that 
determined their assignment. Subjects in the PCS group received a supply of the PCS 
monthly while subjects in both PCS and control groups received a monthly supply of 
MNS.  
 
The study was an open label study. However, laboratory staff members performing CD4 
determinations and exploratory assays were not aware of subject assignment.  
 
b. The protein-calorie supplement (PCS).  
The composition of the PCS was designed based on data collected from 42 HIV-positive 
women with newly diagnosed smear positive tuberculosis by the same group. This study 
quantified nutritional deficits in this group of participants.  
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Compared to the WHO intake recommendations, this study quantified a deficit of 
877Kcal and 42 g of protein per day. The PCS was a porridge (“Dar-uji”) developed from 
local ingredients and taste tested among HIV-TB patients in Study 2-A. It was formulated 
to cover the deficits observed by providing 1062 kcal/d and 42 gm protein/d.  
 
c. The micronutrient supplement (MNS).  
The MNS supplement (DarVite) was a tablet formulated with 1 RDA of the WHO 
micronutrient formulation used by the National AIDS Control Program in Tanzania and 
produced for the study by Tishcon Corporation, Salisbury MD. Subjects were provided a 
one-month (30 tablets) supply at each visit. Each tablet contained 70 mg of vitamin C, 10 
IU of vitamin E acetate, 18 mg of niacinamide, 0.4 mg of folic acid, 2.6 ug of vitamin 
B12, 1.9 mg of vitamin B6, 1.4 mg of vitamin B1 (thiamine) and 1.4 mg of vitamin B2 
(riboflavin). All patients received MNS irrespective of their randomization. 
 
d. Antiretroviral Therapy (ART):  
All patients received antiretroviral medications as per the Tanzania Ministry of Health 
guidelines on treatment of HIV for HIV/TB coinfected individuals.  
 
e. Adherence to PCS, MNS and ART:  
Adherence on the use of PCS, MNS and ART was tracked overtime. During each 
monthly visit participants was asked about their compliance on use of medications and 
the intervention and information documented on CRFs. Our assessment indicated good 
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adherence to the use of the intervention, with greater than 90% use of the supplement by 
participants each month. 
 
f. Data capture tools:  
Standard case report forms (CRFs) piloted in a prior study were used for the current trial. 
All data was collected in Tanzania, justified and transferred electronically to the Data 
Center at Dartmouth College without personal identifiers. 
 
IV. Study Questions 
Primary Study Question: 
What is the association between the intervention (PCS) and a change in CD4 counts in 
patients with HIV and TB, after controlling for other predictors of CD4 count? (i.e. ART 
use, adherence to the intervention and ART, age, education level and BMI, baseline CD4, 
other comorbidities i.e. opportunistic infections and MNS study arm) 
 
Primary Outcome Variable:  
CD4 count change between baseline and after 6 months on ART (8 months on PCS) 
among study subjects. 
 
V. Hypothesis: 
• The change in CD4 count will be greater after 8 months follow up among patients 
receiving the intervention (MNS+PCS) compared to those receiving standard therapy 
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MNS alone 
  
VI. Materials/Methods: 
 Study Design: analysis is done on data from 151 participants randomized to this 
study.  
 
A linear regression model is used for data analysis. Data and prior information has been 
used to critically evaluate the epidemiologic assumptions implied by model and the 
statistical assumptions required by the model. 
 
Our dependent variable (change in CD4) and its associated independent variable (s) have 
been selected based on known knowledge on the influence of these variables on the 
outcome of interest.  
 
A variable selection strategy screened out recorded variables that would be appropriate 
candidates for control (such variables include all variables which are influenced by the 
outcome and our exposure of interest)  
 
The remaining variables (covariates) have further been screened to select few most 
appropriate variables that will be included in the final model. The selection process will 
include an assumption that the omitted variables are not in fact confounders. A variable 
selection algorithm that parallels the disease will therefore be formulated. 
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A “change in estimate method” has been used in selecting variables to be included in the 
model. Candidate variables not in the primary model are added individually to the model, 
one at a time and a note on the change in estimated exposure effect made (if this change 
exceeds a certain amount (e.g., a 10 percent change in the linear regression coefficient 
from the adjusted model compared to that obtained in an unadjusted model) then the 
variable is then identified for inclusion into the final model.  
 
The final model constitutes all identified variables that had the greatest effect in changing 
the estimated exposure effect. The order of their entry into the model follows a 
descending order trend from the variables that resulted in the greatest change in estimate 
to the least. 
 
Regressor (independent) variables to be included in the final model (through the process 
outlined above) are selected based on their conceived relationship with our outcome of 
interest i.e. their influence on CD4 count. 
 
The study was powered to look into the influence of PCS on CD4 change, from baseline 
up to 6 months after ART initiation, thus encompassing use of the supplement for 8 
months. Analysis has therefore focused on the effect of the exposure to a change in CD4 
between the intervention and control groups, as a continuous variable.  
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In addressing selection bias, preserve randomization and to generalize to a real life 
situation, all 151 patients enrolled in the study are included in the intention-to-treat 
analysis. All baseline characteristics are compared among the Intervention and the control 
groups. All identified confounder variables, such as age, BMI, baseline CD4 compliance 
to HAART medication etc. are analyzed and adjusted for appropriately in the proposed 
multivariable linear regression model.  
 
VII: Statistical Methods 
Data has been collected using filemaker version 11 and Microsoft Excel. Data were 
analyzed using Statistical Analysis Software (SAS) version 9.3. 
 
VIII: Results: 
Demographic characteristics of the two groups were compared reporting on the median 
and interquartile range [IQR] for continuous variables and frequency and percent for 
categorical variables. All comparisons made on the variables between the two groups for 
statistically significant difference at the level of 0.05. (Table 1 below) 
 
First, we ran a crude analysis to evaluate the distribution of the predictor variable (CD4) 
and at baseline, presented on histograms below are both the crude and log transformed 
distributions for the MNS and PCS-MNS groups.  
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Table 1. Comparisons made on the variables between the two groups for statistically 
significant difference at the level of 0.05. 
 
 
 
The two arms were fairly balanced with 79 participants in the control arm (MNS) and 72 
participants in the intervention arm (PCS). On comparing demographic characteristics 
between the two groups we found that the median ages for the two groups were almost 
identical, those randomized to the intervention group (PCS) were slightly older (37.5 
years) as compared to those randomized to the control arm, MNS (36 years). Participants 
in the PCS group had slightly higher baseline CD4 counts (201 vs. 193), they also had 
slightly higher BMI (20.4 vs. 20.1) and slightly lower daily household expenditure ($3.5 
vs. $4). None of these parameters of assessment were statistically significant between the 
two groups.  
 
Figure 1 below shows the histogram for the distribution of baseline CD4 count between 
the two groups under comparison. Both the crude and log transformed results showed 
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similar patterns, with most participants having CD4 count of less than 500. 
 
 
 
Figure 1. Histograms for the distribution of baseline CD4 count between the two groups 
under comparison. 
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Also analyzed and compared were distributions of other important characteristics of 
interest, which included age at time of enrollment and BMI. Both these are presented in 
histograms below. Baseline BMI’s all seem to follow the same pattern. They are slightly 
skewed to the right. 
 
 
Figure 2. Histograms of distributions of BMI. 
 
Crude analysis for age at time of enrollment presented by the histograms below reflects 
an almost normal distribution fit on a curve. 
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Figure 3. Histograms of distributions of age at time of enrollment. 
 
The histogram below shows the distribution of the primary outcome of interest, i.e. CD4 
count change, between baseline and after 6 months on ART (8 months on PCS) among 
study subjects was measured as a continuous variable. Average change in CD4 count was 
similar for both groups (204 vs. 207 units between baseline and 8 months) 
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Figure 4. Distribution of the primary outcome of interest. 
 
We then used a linear regression model to fit all variables that are thought to be 
associated with randomization (the intervention) based on the results of the univariate 
analysis and literature review for historical variables that have been linked with the 
intervention among HIV-TB co-infected individuals. In order to evaluate for potential 
confounding we examined the effect of each variable in the crude estimate of association 
between the main predictor of interest and our outcome, comparing the adjusted estimate 
of association.  If the adjusted estimate differs from the crude by more than 10%, we then 
retained that variable for inclusion in our final multivariate model. After having evaluated 
all potential confounders in this fashion, we built a comprehensive multivariable model. 
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Table 2. The univariate analysis for variables associated with randomization  
 
 
On a univariate analysis to examine the association between our predictor variables and 
randomization (the intervention) using a simple linear regression; we found that age and 
baseline BMI were both significantly associated with the intervention at the level of 
significance of 0.05, but no other factors were found to be associated with CD4 change 
(Table 2 above) 
 
We then began building our final model to include all predictors of the effect of 
randomization and examine for occurrence of confounders; we first selected variables to 
be tested for inclusion in our final model (Table 2), variables were selected based on their 
effect on the point estimate of Randomization (the intervention) at the univariate level, 
we also tested for epidemiologically essential variables and variables from literature 
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review that have historically been shown to be associated with a change in CD4, we 
employed  a 10% change in the adjusted regression coefficient of HIV from the crude 
regression coefficient as our measure to retain the variable in our final model. 
 
We tested one variable at a time in the process calculating percent change in the crude 
regression coefficient using the formula % Change= βcrude - β adjusted / β adjusted (Tables in 
addendum). In our final model we included those variables that changed the crude 
association between the intervention (PCS) and Change in CD4 by 10% or more. Our 
final model included baseline BMI and previous TB. 
 
Building the Model: Simple Linear Regression analysis (See tables in addendum) 
Age increased the regression coefficient of the intervention (PCS) by 237% (adjusted 
regression coefficient= 0.03461 up from -0.02522), the change was however not 
statistically significant (P=0.1). Baseline BMI increased the regression coefficient of the 
intervention (PCS) by 615% (adjusted regression coefficient= 0.13781 up from 
m-0.02522), this too was not statistically significant, (P=0.1044).  
 
A non-statistically significant (P=0.7393) increase of 117% was also observed when 
baseline CD4 was added to the model (adjusted regression coefficient= -0.05494 up from 
-0.02522). Daily household expenditure did not have a statistically significant influence 
on the intervention, however it did change the parameter estimate by 243% (adjusted 
regression coefficient= 0.03619 up from -0.02522), (P=0.8340). Prior TB disease did also 
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influence a change in parameter estimate by 336%, this too was not statistically 
significant (adjusted regression coefficient= 0.05959 up from -0.02522), (P=0.8599). 
 
Even though the addition of the various predictors for CD4 change did not result to 
statistically significant difference, they all yielded a change in parameter estimate 
(regression coefficient). We then continued building the model, adding to the model with 
the greatest percentage change in parameter estimate. 
 
We added previous TB disease experience to the model after retaining Baseline BMI, the 
regression coefficient of the intervention increased by 104%(regression coefficient= 
0.28107, P=0.0648). Adding daily household expenditure changed our point estimate by 
59% (P=0.1947), adding age increased out regression coefficient by 9.1% (P=0.0771). 
Adding baseline BMI had the least effect, it resulted to a decrease in parameter estimate 
/regression coefficient by 20%, and was not statistically significant, (P=0.1726). 
 
Addition of items to the model that had the greatest effect did not yield any significant 
improvement to the changes in regression coefficient, neither did they improve on 
statistical significance.  
 
When testing for interaction between baseline BMI and previous TB treatment we found 
none between the two variables that affect the regression coefficient significantly (not 
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reported), we also found no interaction between daily household expenditure and baseline 
CD4. 
 
Table 3. The multivariate analysis for variables associated with randomization 
 
 
In sum, in our data analysis we found that the PCS intervention had no significant effect 
on change in CD4, after adjusting for baseline BMI and previous TB disease among 
study participants,(regression coefficient= 0.28107, t=0.6, P= 0.0648). This model was by 
far the best fit model of the relationship. 
 
Conclusion: 
IX: Strengths and Limitations 
First, this is an observational study and, thus, is susceptible to confounding effects that 
hold back clear establishment of causal inference. Second, even though all our 
participants were HIV seropositive individuals with pulmonary TB, their adherence to 
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ART rates was high in both groups, and this could have masked an effect of the 
intervention. 
 
Missing CD4 data in some of the subjects due to LTFU or withdrawal from the study 
could also have obscured an effect of the PCS. However, the attrition was almost 
balanced between the two groups 14 vs. 11 for MNS vs. PCS respectively, and the 
proportion missing was small. 
 
The study sample size small, the study was initially powered at 180 patients, however it 
was cut short due to funding at 151. The resulting 29 subjects less cohort could have 
resulted to non-observable true effects of the intervention if any. 
 
Strengths: 
This data analysis has several notable strengths; To our understanding, this study is the 
first to look at the association between nutritional supplement and CD4 change among 
HIV- infected TB patients on treatment. 
 
Careful consideration of clinical, and epidemiological confounders with relatively 
complete data allowed us to control for these factors during analysis. 
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X: Importance and Future Directions: 
This study assessed CD4 change as a surrogate marker for disease progression in the 
presence of nutritional supplementation. Results of our study could help shed light on the 
question of the role played by the protein calorie supplement. Further studies in this area 
are needed that further address the role of nutrition in TB and HIV treatment.  
 
The findings from this study could allow for more cost-effective resource allocation and 
targeted nutritional interventions in the community among patients infected with TB and 
HIV.  
 
XI: Role in the study: 
The investigator provided clinical care to participants involved in the study. He collected 
the data, oversaw its management and analysis. The investigator worked hand in hand 
with the principal investigator and academic professors in the process. He then orally 
presented the results to his thesis committee and invited guests and later   wrote up and 
reported the results in this final written thesis. 
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